RE: [TDI-discuss] Fw: Open Source Stem Cell R&D (fwd)

["Will Rosellini" <>]

I've now read about 100 articles like this, but haven't found any that
actually talk about how data from scientific experiments should be
integrated? Is this any different than the human genome project model?  Is
there a working model?  Do you see these types of projects using SBML?  

Sounds like a sourceforge for biomedical research. I'm trying to get my head
around a very large topic which is also unexplored, so any references would
be appreciated.  I've read most of Maurer and Rai's papers on the subject,
but wanted to see if anyone else had come across interesting articles.  

Thanks in advance

-Will Rosellini

-----Original Message-----
From: 
[">mailto:] On Behalf Of Luca Brivio
Sent: Sunday, January 23, 2005 7:27 PM
To: 
Subject: [TDI-discuss] Fw: Open Source Stem Cell R&D (fwd)


This seems to be interesting, although not so related to TDI...

Begin forwarded message:

Date: Sat, 22 Jan 2005 18:23:25 +0100 (CET)
From: Andreas Tille <>
To: Debian Med Project List <>
Subject: Open Source Stem Cell R&D (fwd)


Hi,

I did not really found a download or a license but if there is any interest
someone might do a more detailed research on the home page

        http://usbiodefense.com/news_012105.php

which seams responsible for the message on LinuxMedNews:


http://linuxmednews.com/linuxmednews/1106324091/index_html


U.S. BioDefense to Launch Open Source Platform for Rapid Stem Cell Research
and Development. Read on for the complete announcement.

City of Industry, CA   January 21, 2005 - U.S. BioDefense, Inc. (OTCBB:
UBDF)
announced today that it is developing an Open Source Stem Cell Research
Platform to leverage the distributed power of open source development. The
Open Source Stem Cell Research Platform will allow researchers at
Universities, Government Agencies, and Fortune 500 companies to read,
distribute, modify and contribute to stem cell and biotechnology research in
an efficient and streamlined method. The platform which can be used as an
Intranet or online will provide access to bioinformatic tools and serve as a
robust utility for the rapid evolution of Stem Cell technology research,
development, and commercialization.

U.S. BioDefense CEO David Chin stated,  We intend to quickly scale up
revenues by focusing on selling Open Source collaborative technology
research and transfer tools as well as commercializing leading edge
technology. The proliferation of open source development to industries
beyond software has prompted U.S. BioDefense to aggressively lead the drive
in implementing the philosophy and benefits to the emerging stem cell
industry. We are positioning ourselves at the nucleus of Stem Cell research
and development tools in order to leverage the potential of California's $3
Billion Stem Cell Research Fund and our Department of Defense SBIR Grant
response related to Embryonic Stem Cell technology for Bioengineered skin
commercialization.

U.S. BioDefense is aggressively pursuing its technology transfer initiative
by incorporating the distributed power of open source development in
individual biotechnology fields related to biodefense research beginning
with its Stem Cell commercialization initiative. The Open Source Stem Cell
Research Platform being developed by U.S. BioDefense is an adaptation of the
monumental open source movement in software development that has also been
embraced by large technology companies like IBM (NYSE: IBM), Novell and Sun
Microsystems
(Nasdaq:
SUNW).

According to Wired Magazine recently the idea of open source biotechnology
has been gaining momentum with the introduction of BIOS, the Biological
Innovation for Open Society (www.bios.net), a non profit with the support of
The Rockefeller Foundation encompassing the creative use of living systems
and their environment, and with the implementation of open source principles
and development methods in the field of bioinformatics. According to BIOS 
web site
the organization will create a mechanism  BioForge  by which like-minded
individuals and agencies can collaborate with optimum effectiveness to solve
problems and create technologies under an open-access regime. The goal of
BioForge is to forge a dynamic protected commons of enabling technologies
that will be available to the worldwide inventive community for use in
improvement and new innovations. The VA Software SourceForge.net Open Source
network provides a scalable solution for empowering development teams across
the diverse worldwide Open Source community. Today, SourceForge.net is the
world's largest Open Source software development web site, hosting more than
90,000 projects and over 950,000 registered users. OSTG receives more than
230 million page views and over 16 million unique visitors every single
month.

About U.S. BioDefense, Inc.

U.S. BioDefense is a Department of Defense central contractor that
researches, develops, and commercializes leading-edge biotechnology. U.S.
BioDefense recently announced that it had filed its Small Business
Innovation Research
(SBIR) Grant proposal Number C051-117-0060 with the Department of Defense
Chemical Biological Defense Agency in response to SBIR (dodsbir.net) Topic
number CBD05-117 'Stem Cell Technology And Autologous Bioengineered Skin For
The Treatment of Cutaneous Vesicant Injury'. U.S. BioDefense recently
sponsored the Project T2 Technology Transfer Conference, the nation's
leading showcase of new university technologies, being hosted at the
Wilshire Grand Hotel in Los Angeles, CA. Other sponsors
(http://www.projectt2.org/sponsors.htm)
include
Southern California Edison, Latham & Watkins, Morrison & Foerster,
PricewaterhouseCoopers, Canadian Consulate General, and Genzyme (NYSE:
GENZ). U.S. BioDefense, Inc. recently entered into a Commercial Evaluation
License Agreement with the National Institutes of Health (NIH). The
biotechnology is related to a method for universal inactivation of viruses,
parasites and tumor cells. These inactivated agents can be used as vaccines
against the diseases caused by such viruses, parasites and tumor cells.
Hence, the immunogenic of the agent as a whole is maintained and can be
safely used for vaccination without the threat of infection. U.S.
BioDefense, Inc. intends to conduct laboratory experiments under this
Agreement to evaluate the suitability for commercial development.
Furthermore, U.S. BioDefense, Inc. has agreed to provide the facilities,
personnel, and expertise to evaluate the commercial applications. NIH's
bioterrorism budgets have jumped from $53 million in 2001 to $1.7 Billion in
2005.

Safe Harbor Statement Forward-Looking Statements Included in this release
are certain  forward-looking'' statements, involving risks and
uncertainties, which are covered by the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's financial performance. Such statements are based on
management's current expectations and are subject to certain factors, risks
and uncertainties that may cause actual results, events and performance to
differ materially from those referred to or implied by such statements. In
addition, actual future results may differ materially from those
anticipated, depending on a variety of factors, including continued
maintenance of favorable license arrangements, success of market research
identifying new product opportunities, successful introduction of new
products, continued product innovation, the success of enhancements to the
Company's brand image, sales and earnings growth, ability to attract and
retain key personnel, and general economic conditions affecting consumer
spending, including uncertainties relating to global political conditions,
such as terrorism. Information with respect to important factors that should
be considered is contained in the Company's Annual Report on Form 10-K as
filed with the Securities and Exchange Commission. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. The Company does not intend to update any of the
forward-looking statements after the date of this release to conform these
statements to actual results or to changes in its expectations, except as
may be required by law.

CONTACT:
U.S. BioDefense, Inc.
David Chin, 626-961-0562



               <  | Washington Monthly: The Best Care Anywhere  >



-- 
To UNSUBSCRIBE, email to 
with a subject of "unsubscribe". Trouble? Contact




-- 
Luca Brivio

Web:		http://icebrook.altervista.org
Jabber:		

________________________________________________________________________

"Homo sum: humani nil a me alienum puto" (P. Terentius Afer)
________________________________________________________________________